BM4SIT is a health project supported by the European Union
Latest News
  • This page is not being updated since 11th August, 2020. For updates and latest news please visit this site.

Could hacking the immune system cure allergies?

January 29th, 2019
HORIZON - The EU Research and Innovation Magazine

Scientists are redesigning natural allergens to help the immune system defend against them, in a move that could eliminate the side effects and lifelong medication of treating allergies - the most common chronic condition in Europe.

Click here for the full text by Sandrine Ceurstemont

  

BM4SIT clinical trials

December 18th, 2018
BM4SIT Clinical Trials

Following the successful vitamin D3 clinical trial and the positive outcome of the toxicological analysis of the hypoallergenic drug product BM41, the BM4SIT consortium decided to continue with two clinical trials:

 

  • In a follow-up of the first vitamin D3 trial, to evaluate the added value of vitD3 as adjuvant we will perform a phase IIa randomized, DBPC study with a subcutaneously administered, approved birch pollen AIT vaccine registered product (Alutard SQ) ± vitamin D3 (Zemplar).This clinical study will be performed at the AMC in Amsterdam, The Netherlands.
  • In a first in man, Phase I/IIa DBPC trial with BM41 plus Alutard SQ as an external comparator, both safety and partly efficacy of the drug product BM41 administered subcutaneously will be assessed. The BM41 trial will be performed at the Odense University Hospital (OUH) in Odense, Denmark.

 

 

Presentation of recent BM4SIT results at the Chair and Institute of Environmental Medicine, UNIKA-T / IEM in Augsburg

December 17th, 2018
BM4SIT Seminar

Dr. Lorenz Aglas from the University of Salzburg (PLUS) presented his recent results of the project BM4SIT during a seminar at the Chair and Institute of Environmental Medicine, UNIKAT-T / IEM in Augsburg, Germany. The title of his presentation was "The birch pollenome - novel perceptions on birch pollen sensitization and therapeutic strategies". The presentation gave the scientific community the chance to inform themselves about recent achievements of the project BM4SIT.

Foto: © UNIKA-T / IEM

 

 

 

Interested in participating in a clinical trial?

 

November 26th, 2018
BM4SIT Clinical Trial

The AMC (Academic Medical Center) is currently looking for birch pollen allergic patients interested to participate in the BM4SIT clinical trial. For further information click here.

 

 

Awards for the project BM4SIT 

 

December 3rd, 2018
Award for BM4SIT

The BM4SIT-Homepage Team is happy to announce that Lorenz Aglas from the University of Salzburg (PLUS) was awarded with the URSULA and FRITZ MELCHERS THESIS PRIZE of the Austrian Society for Allergology and Immunology (ÖGAI) and also with the AK SCIENCE PRIZE of the Austrian chamber of labour (Salzburg) for his outstanding research results. His thesis/research was done as part of the project BM4SIT and paved the way for the ongoing First-in-Man clinical trial.  

Congratulations!

 

 

Presentation of BM4SIT results at the NextGeneration ÖGAIng Meeting 2018 in Vienna 

 

November 12th, 2018
BM4SIT Presentation

The "NextGeneration ÖGAIng Meeting 2018" by the Austrian Society of Allergy and Immunology took place at the "Schutzhaus zur Zukunft" in the beautiful city of Vienna, Austria. It was an inspiring event for all conference participants. At this point, thanks to the organizing committee for realizing such a great event!

In course of a session of scientific interviews, Lorenz Aglas from the University of Salzburg (PLUS) was interviewed by Edward Knol (departments of Immunology and Dermatology/Allergology at the University Medical Center Utrecht) and had the opportunity to present his newest results to the audience. The title of his presentation was "In vivo induction of IgG antibodies towards Bet v 1 and associated food allergens by a hypoallergenic birch pollen allergy AIT vaccine candidate". The presentation gave the scientific community the chance to inform themselves about recent achievements of the project BM4SIT.

Foto: © L. Aglas, PLUS

 

 

Presentation of new BM4SIT data at the EAACI 2018 in Munich 

 

May 26-30th, 2018
BM4SIT Presentation

The "EAACI 2018 Annual Congress" took place in the beautiful city of Munich, Germany. It was an amazing event for conference delegates. At this point, thanks to the organizing committee for realizing this amazing event.

Lorenz Aglas from the University of Salzburg (PLUS) presented his results during a poster discussion session. The title of his presentation was "The hypoallergenic birch pollen allergy AIT candidate BM4 induces cross-reactive IgG antibodies towards Bet v 1 and associated food allergens". The presentation gave the scientific community the chance to inform themselves about recent achievements of the project BM4SIT.

We further would like to congratulate the presenter, Lorenz Aglas, for winning the EAACI 2018 travel grant. Congratulations!

Foto: © L. Aglas, PLUS

 

 

Results from the BM4SIT were presented at the ISMA 2017 in Luxembourg

 

November 9-11th, 2017
BM4SIT Poster Presentation

From November 9-11th, 2017 the BM4SIT Team was proud to present a poster at the ISMA 2017  (International Symposium on Molecular Allergology Focused Meeting), taking place in Luxembourg. The meeting was a great success and the poster gave insights into project progress and recent achievements.

      

 

BM4SIT project presentations at the SIICA Congress 2017 in Bari, Italy

 

  

   

 

May 28th-31st, 2017
BM4SIT at the SIICA congress

The BM4SIT consortium has organized scientific presentations that took place at the congress of the Italian society of immunology, clinical immunology and allergology (SIICA) 2017 in Bari, Italy from 28th to 31th of May 2017.

BM4SIT Consortium Meeting 2016 in Amsterdam, the Netherlands

  

   

Meeting participants (from left to right):
1st row:  E.
C. de Jong, AMC; D. van Egmond, AMC; E. de Groot, AMC; A. Neubauer, Biomay; V. Ranta-Panula, UTU
2nd row: O. Pfaar, Allergy Center Wiesbaden; F. Stolz, Biomay; C. Bindslev-Jensen, OUH; W. Fokkens, AMC; R. van Ree, AMC; L. Zuidmeer-Jongejan, AMC; C.M. van Drunen, AMC; M. Wallner, PLUS; L. van Rijt, AMC
Not on picture: F. Ferreira, PLUS; K. Lemmens, Clinical Trial Center Maastricht  

Foto: © L. Aglas, PLUS

November 21st-22nd, 2016
BM4SIT Consortium Meeting

The BM4SIT consortium meeting that took place in Amsterdam, the Netherlands from the 21st to 22nd of November 2016 was very successful. Representatives from almost all project partners were present, including the Academic Medical Center Amsterdam (AMC), the University of Salzburg (PLUS), the University of Turku (UTU), the Allergy Center Wiesbaden, Biomay AG and the Odense University Hospital (OUH).


The following topics were discussed during the meeting:

  • Drug development and production
  • Quality control of drug substance
  • Aptamers
  • Outcome of first clinical trial
  • Immunological testing in vitamin D3 trial
  • Protocol of second clinical trial defined
  • Results from toxicity study 

 

 

The project BM4SIT was presented at the EAACI 2016 Annual Congress in Vienna, Austria

 

June 11-15th, 2016
BM4SIT Poster Presentations

The "EAACI 2016 Annual Congress" took place in the beautiful city of Vienna, Austria. It was an amazing event for all participants. At this point, thanks to the organizing committee for realizing this special event.

Lorenz Aglas from the University of Salzburg (PLUS) presented his results during a poster discussion session. The title of his presentation was "Development of an aptamer-based tool for quality control of a birch pollen immunotherapy vaccine". He also presented a second poster entitled, "Immunologic evaluation of the hypoallergenic birch pollen AIT vaccine candidate BM4 during toxicity testing". Both presentations were very interesting and gave the scientific community the chance to inform themselves about the project BM4SIT.

Foto: © L. Aglas, PLUS

 

 

Presentation of αBM4-specific Aptamers at the "3rd Oxford Symposium on Aptamers" in Oxford, United Kingdom

April 4-5th, 2016
BM4SIT Poster Presentation

The "3rd Oxford Symposium on Aptamers", that took place in Oxford, United Kingdom, was a success for all participants. At this point, thanks to the organizing committee for realizing such an informative event on aptamers.

Lorenz Aglas from the University of Salzburg (PLUS) presented his results on a poster entitled "Development of an enzyme-linked apta-sorbent assay (ELASA) for the quality control of a birch pollen immunotherapy vaccine", which was very successful.

Foto and Poster: © L. Aglas, PLUS

 

 

The BM4SIT Homepage is ONLINE

 

July 27th, 2015
BM4SIT Homepage: Online

Today, the 27th of July 2015, is the official launching of the BM4SIT homepage.

 

 

BM4SIT Meeting Vienna 2015

Meeting participants (from left to right):
1st row: F. Stolz, Biomay; F. Ferreira, PLUS; I. Terreehorst, AMC; R. van Ree, AMC; E.
C. de Jong, AMC; L. Knaepen, CTCM; A. Neubauer, Biomay; C. de Bont, CTCM
2nd row: L. Aglas, PLUS; O. Pfaar, Allergy Center Wiesbaden; C.M. van Drunen, AMC; L. Zuidmeer-Jongejan, AMC; C. Bindslev-Jensen, OUH; M. Jutel, ALL-MED
Foto: © M. Wallner, PLUS

May 18rd-19th, 2015
BM4SIT Meeting: Vienna

The BM4SIT meeting 2015 took place at Biomay in Vienna. After a summary of all changes in the project and the proposed actions, presentations on the recent progress on the BM4/ vitamin D3 program were presented.
The consortium discussed the scientific progress of the project, the protocols of the clinical trials, and the dissemination strategy. Furthermore, to-dos and milestones for the next project period were reviewed. 

Kickoff Meeting Amsterdam

February 3rd-4th, 2014
Kickoff Meeting: Amsterdam

BM4SIT was officially launched on February 3rd at the AMC in Amsterdam. After presentations on recent progress on the BM4/ vitamin D3 program, the consortium decided on to-dos and milestones for the first project period. 

 

 


 

Links to:

  • Newsletter
  • News Archive
  • Meetings